I think you see provincial governments doing that to a certain extent. On provincial formularies there are a number of single-source generic drugs that get treated with what's called exemption status, or something like that. They're not necessarily subjected to the price regulation scheme that the province may have in place that determines listing on formularies, so there's a certain amount of discrimination in favour of a particular generic formulation.
I think what we see illustrating that as well is that just addressing the price of a particular drug in the marketplace isn't necessarily enough to prevent shortages, and that points to the multifactorial nature of the problem. The biggest issues are global. A manufacturing problem in one country you can perhaps fix, but if you have a global shortage of an active pharmaceutical ingredient, that's a major problem, because no one can make the product if for some reason the source of supply of the active pharmaceutical ingredient has failed.
It points to the need for activity in terms of market incentives and disincentives. We need action around regulatory issues—